Investor Relations - Curis

Month Year

Investor Alerts

Sep 3, 2014

Curis to Present at the 13th Annual BIO Investor Forum

LEXINGTON, Mass., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Aug 27, 2014

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Aug 7, 2014

Curis Reports Second Quarter 2014 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

LEXINGTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jul 31, 2014

Curis to Release Second Quarter 2014 Financial Results and Hold Conference Call on August 7, 2014

LEXINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Jun 23, 2014

Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study of Erivedge(R) (vismodegib) in Idiopathic Pulmonary Fibrosis

Filing Triggers $3 Million Milestone Payment to Curis

LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jun 5, 2014

Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial

Expansion Phase to Include Patients With Ovarian Cancer and Certain Hematologic Malignancies

LEXINGTON, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Jun 3, 2014

Curis Announces Executive Management Transition

Ali Fattaey, Ph.D. Promoted to President and Chief Executive Officer

LEXINGTON, Mass., June 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced the...
May 29, 2014

Curis to Present at the Jefferies 2014 Global Healthcare Conference

LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
May 23, 2014

Curis Announces Abstracts for Its Partnered Programs, Erivedge(R) and Debio 0932 to be Presented at the 2014 ASCO Annual Meeting

LEXINGTON, Mass., May 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
May 18, 2014

Curis to Present at the JMP Securities Healthcare Conference

LEXINGTON, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
May 8, 2014

Curis Reports First Quarter 2014 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

LEXINGTON, Mass., May 8, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today...
May 1, 2014

Curis to Release First Quarter 2014 Financial Results and Hold Conference Call on May 8, 2014

LEXINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Apr 30, 2014

Curis to Present at the Deutsche Bank 39th Annual Health Care Conference

LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Apr 30, 2014

Curis Announces U.S. Patent Issuance Covering CUDC-907 Composition-of-Matter

Dual HDAC and PI3K Inhibitor in Ongoing Phase 1 Study in Patients With Relapsed/ Refractory Lymphoma and Multiple Myeloma

LEXINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Apr 7, 2014

Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

Debio 0932 Demonstrated Anti-Tumor Activity and Synergy With Various SOC Agents in In Vitro and Xenograft Models of NSCLC and RCC

LAUSANNE, Switzerland and LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of...
Apr 7, 2014

Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014

CUDC-907 Modulates Expression of Certain Cytokines/ Chemokines, Potentially Targeting Tumor Microenvironment in Addition to Direct Effects on Cancer Cells

LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Apr 2, 2014

Curis to Present at the 13th Annual Needham Healthcare Conference

LEXINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Mar 31, 2014

Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427

Curis Expects to Reinitiate Enrollment in Single Agent Phase 1 Study of CUDC-427 in Patients With Solid Tumors or Lymphoma

LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Mar 30, 2014

Curis Announces Presentation of Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting

LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Mar 4, 2014

Curis to Present at the 26th Annual ROTH Conference

LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Feb 23, 2014

Curis to Present at the Cowen and Company 34th Annual Health Care Conference

LEXINGTON, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Feb 20, 2014

Curis Reports Fourth Quarter and Year-End 2013 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EST

LEXINGTON, Mass., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Feb 19, 2014

Curis to Present at the RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Feb 13, 2014

Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014

LEXINGTON, Mass., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Feb 5, 2014

Curis to Present at the Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Dec 9, 2013

Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting

CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity

LEXINGTON, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Dec 4, 2013

Curis to Present at the Oppenheimer 24th Annual Healthcare Conference

LEXINGTON, Mass., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Nov 25, 2013

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Nov 5, 2013

Curis Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update

CUDC-427 Phase 1 Trial Placed on Partial Clinical Hold by FDA

LEXINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop novel, targeted drug candidates for the treatment of human cancers,...
Oct 22, 2013

Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus

Designed to Target Advanced Metastatic Renal Cell Carcinoma, the Study Will Determine the Maximum Tolerated Dose of Debio 0932 in Combination With Everolimus

LAUSANNE, Switzerland and LEXINGTON, Mass., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of...
Oct 3, 2013

Curis Announces Initiation of a Roche-Sponsored Phase 1b/2 Study of Erivedge(R) (vismodegib) in Relapsed/Refractory AML and High Risk MDS

AML and MDS Represent Non-Mutation Driven Hedgehog Pathway Malignancies

LEXINGTON, Mass., Oct. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that...
Sep 26, 2013

Curis to Webcast Investor and Analyst Day in New York City

LEXINGTON, Mass., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers,...
Sep 4, 2013

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Aug 6, 2013

Curis to Present at the 2013 Wedbush Life Sciences Management Access Conference

LEXINGTON, Mass., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Aug 4, 2013

Curis Reports Second Quarter 2013 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

LEXINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Jul 29, 2013

Curis to Release Second Quarter 2013 Financial Results and Hold Conference Call on August 5, 2013

LEXINGTON, Mass., July 29, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Jul 25, 2013

Curis Announces Initiation of a Clinical Trial of CUDC-427 In Advanced Malignancies

Expansion Cohort Primarily to Include Ovarian and Fallopian Tube Cancers

LEXINGTON, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Jul 15, 2013

Curis Announces the Conditional Approval of Erivedge(R) in the European Union

Triggers $6 Million Milestone Payment to Curis

LEXINGTON, Mass., July 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human...
Jul 13, 2013

Curis Strengthens Leadership Team With Appointments of Jaye Viner, M.D. as Chief Medical Officer and Tania Chander, Pharm.D. as VP of Product Development

Dr. Viner Brings Significant Drug Development and Molecular Oncology Expertise

LEXINGTON, Mass., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop next generation targeted drug candidates for the...
Jun 20, 2013

Curis Announces U.S. Patent Issuance Strengthening Intellectual Property Position of PI3K-HDAC Inhibitor CUDC-907

LEXINGTON, Mass., June 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of various...
Jun 3, 2013

Curis Announces CUDC-427 (GDC-0917) Phase I Clinical Data Presented at ASCO 2013 Annual Meeting

LEXINGTON, Mass., June 3, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Jun 3, 2013

Curis to Participate in Two Upcoming Investor Events

LEXINGTON, Mass., July 3, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 31, 2013

Curis Announces Appointment of Mani Mohindru, Ph.D., as Vice President of Corporate Strategy and Investor Relations

LEXINGTON, Mass., May 31, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 30, 2013

Curis to Present at the Jefferies 2013 Global Healthcare Conference

LEXINGTON, Mass., May 30, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 22, 2013

Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference

LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 16, 2013

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

LEXINGTON, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 11, 2013

Curis to Present at the 2013 Wells Fargo Securities Healthcare Conference

LEXINGTON, Mass., June 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 9, 2013

Curis Announces Approval of Erivedge(R) in Australia

Expands Global Erivedge Patient Access and Commercial Opportunity

LEXINGTON, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Apr 29, 2013

Curis Reports First Quarter 2013 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

LEXINGTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Apr 26, 2013

Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union

Recommended as Treatment for Advanced Basal Cell Carcinoma

LEXINGTON, Mass., April 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Apr 24, 2013

Curis to Present at the Needham 12th Annual Healthcare Conference

LEXINGTON, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Apr 23, 2013

Curis to Release First Quarter 2013 Financial Results and Hold Conference Call on April 30, 2013

LEXINGTON, Mass., April 23, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced...
Mar 29, 2013

Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

LEXINGTON, Mass., March 29, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Mar 11, 2013

Curis to Present at the Roth Capital Partners 25th Annual Growth Stock Conference

LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Feb 25, 2013

Curis to Present at the Cowen and Company 33rd Annual Health Care Conference

LEXINGTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Feb 20, 2013

Curis Reports Fourth Quarter and Year-End 2012 Financial Results

Conference Call to Discuss Results and Provide 2013 Outlook Today at 9:00 a.m. EST

LEXINGTON, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Feb 19, 2013

Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer

Brings Over 20 Years of Experience in Cancer Research, Drug Discovery and Development, Including Nexavar® (sorafenib) and PD-0332991 (palbociclib)

LEXINGTON, Mass., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Feb 15, 2013

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Feb 13, 2013

Curis to Release Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call on February 20, 2013

LEXINGTON, Mass., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced...
Feb 11, 2013

Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors

LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
Jan 24, 2013

Curis Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907

Curis Earns $350,000 in Milestone Payments From The Leukemia & Lymphoma Society

LEXINGTON, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer...

Show per page